Bijorn in USA

[Imperative Care Stroke @ImpCare_Stroke]

In 2013, ADAPT changed the conversation around aspiration thrombectomy. So what comes next?

In the latest NeuroNews (@NN_publishing) feature, Dr. Quill Turk reflects on the evolution of aspiration thrombectomy and the innovations that helped shape the ADAPT 2.0 technique from intracranial access and asymmetric clot engagement to Continuous Dual AspiraTion (CDAT).

🔗 Read the full feature: https://t.co/L9pfBO4VOW

#stroke #neurointervention
Rx only. ISI: https://t.co/20ZwfceFWm

[Imperative Care Stroke @ImpCare_Stroke]

Prepared for the unexpected?

In the latest NeuroNews (@NN_publishing) article, Dr. Josh Abecassis (@drjoshabecassis) discusses how the ADAPT 2.0 technique and Zoom Stack help standardize setup while adapting to changing anatomy, vessel locations, and procedural demands throughout a case. With a focused stack of two to three catheters, physicians can maintain a consistent setup while treating a broad range of occlusions.

The Zoom Stack helps you stay ready for what's next.

🔗Read the full feature: https://t.co/L9pfBO4VOW

#stroke #neurointervention
Rx only. ISI: https://t.co/20ZwfceFWm

[Imperative Care Stroke @ImpCare_Stroke]

Aim to (SIM)plify Type II and Type III arches with #ZoomSIM.

#BuiltToADAPT
Rx only. ISI: https://t.co/9GLPGxFsrr

[Imperative Care Stroke @ImpCare_Stroke]

📢 New Data Presented at #ESOC2026

A pre-specified analysis of the #ImperativeTrial evaluated aspiration thrombectomy alone vs. a combined approach with IV thrombolysis.

The analysis suggests that aspiration thrombectomy alone may result in higher rates of successful reperfusion and a reduced need for rescue devices.

Aspiration Only vs. Combined Approach with IV Thrombolysis:
✅ 92% vs 81% – rate of mTICI ≥ 2b
✅ 2% vs. 10% – use of rescue devices to achieve mTICI ≥ 2b

Published in JNIS, read the research led by Dr. Maxim Mokin et al.: https://t.co/5hOC6qhkGR

#stroke #neruointervention

Rx only. ISI: https://t.co/20ZwfcfdLU

[Imperative Care Stroke @ImpCare_Stroke]

📢 ICYMI: Last week we announced first patients enrolled in the ADAPT 2.0 Clinical Study. The study is a prospective, multi-center, observational study evaluating the effectiveness, safety and clinical outcomes of the ADAPT 2.0 technique using the Zoom Stroke System to treat patients with acute ischemic stroke.

We believe this study represents an important step in advancing ADAPT 2.0 as a first-line thrombectomy strategy and in generating rigorous, data-driven evidence to support ongoing innovation in stroke intervention.

🔗 Read the full press release: https://t.co/bXADkkzQZy

#ZoomStrokeSystem #stroke #neurointervention
Rx only. ISI: https://t.co/20ZwfceFWm

[Imperative Care Stroke @ImpCare_Stroke]

NEWS: 📢 Today we announced the initiation of the ADAPT 2.0 Study, a prospective, multi-center, observational study evaluating the effectiveness, safety and clinical outcomes of the ADAPT 2.0 technique using the Zoom Stroke System to treat patients with acute ischemic stroke.

The ADAPT 2.0 technique is a system-driven approach that incorporates the delivery of a 0.088” intracranial access catheter closer to the clot, asymmetric aspiration designed to facilitate more complete clot ingestion, and the consistent application of the Continuous Dual AspiraTion (CDAT).

🔗 Read the full press release: https://t.co/bXADkkAoP6

#ZoomStrokeSystem #stroke #neurointervention
Rx only. ISI: https://t.co/20ZwfcfdLU

[Imperative Care Stroke @ImpCare_Stroke]

Advancing stroke care takes clinical collaboration.

Yesterday we announced the ADAPT 2.0 Clinical Study, a prospective, multi-center, observational study designed to evaluate the effectiveness, safety, and clinical outcomes of the ADAPT 2.0 technique using the Zoom Stroke System for patients with acute ischemic stroke.

Through close collaboration with physicians, we’re working to advance evidence-based stroke treatment to support patient outcomes.

🔗 Read the full press release: https://t.co/bXADkkzQZy

#ZoomStrokeSystem #stroke #neurointervention
Rx only. ISI: https://t.co/20ZwfceFWm

[Imperative Care Stroke @ImpCare_Stroke]

Anatomy varies.
Vessel occlusions can migrate.
Procedural decisions evolve in real time.

🧠That’s why the Zoom Stack is #BuiltToADAPT.

The combined use of Zoom 88 Support, Zoom 7X, and Zoom 4S is designed to navigate challenging anatomy and respond to the dynamic nature of stroke thrombectomy procedures. From arch access to continuous dual aspiration, each component plays a role to support a streamlined ADAPT 2.0 technique.

#ZoomStrokeSystem #stroke #neurointervention
Rx only. ISI: https://t.co/20ZwfceFWm

[Imperative Care Stroke @ImpCare_Stroke]

🧠Zoom Stack: Built to ADAPT to the anatomy.

The Imperative Trial showed difficult Type II and Type III aortic arch anatomy can occur in up to 56% of patients, presenting challenges in stroke access*. Zoom 88 Support + Zoom 6F Insert Catheters allow you to adapt to unique patient anatomies to get out of the arch and into the brain faster.

Choose the stack that is #BuiltToADAPT.

🔗Want to learn more about the Zoom Intracranial Access Portfolio? Visit our website to learn more: https://t.co/7sqnehpvUX

#ZoomStrokeSystem #stroke #neurointervention
Rx only. ISI: https://t.co/20ZwfceFWm

*Mokin et al. Interventional Neuroradiology.2025.

[Bijorn in USA @bradbourg]

@3YearLetterman @BillAckman @X

[Imperative Care Stroke @ImpCare_Stroke]

The Zoom 4S Catheter was built for ease of use, empowering physicians with a device that is designed to address a broad range of occlusions. Through its straight-lumen design, #Zoom4S fits inside #Zoom7X and other larger bore Zoom catheters to provide enhanced support and distal navigation capabilities.

✅ Asymmetric Aspiration: Largest surface area compared to other 4F aspiration catheters
✅ Full Compatibility: Full system compatibility to streamline device set-up for faster, simpler, and more effective stroke cases with reduced catheter exchanges
✅ Enhanced Navigation: Soft distal polymers to improve trackability through challenging distal vasculature

🔗Visit our website to learn more about Zoom 4S, the newest addition to our Zoom Stroke System: https://t.co/GhjkqL8cqp

#neurointervention #stroke
Rx only. ISI: https://t.co/20ZwfcfdLU

[Bijorn in USA @bradbourg]

@bstrand11111 @Lane_Kiffin @OleMiss @OxfordPolice You spelled $.21 /hour wrong

[Imperative Care Stroke @ImpCare_Stroke]

ICYMI: 📢 Yesterday we announced the launch of the new #Zoom4S Catheter for #stroke treatment, along with initial patient cases! Zoom 4S was engineered to simplify your #thrombectomy procedures through:

• A single Zoom stack
• Continuous Dual AspiraTion (#CDAT) on two asymmetric tip catheters
• Reduced device exchanges

🔗 Read the release to learn how you can achieve the benefits of ADAPT 2.0 in a broad range of occlusions with the goal of faster, simpler and more effective procedures: https://t.co/fWqn6Kxeky

#neurointervention
Rx only. ISI: https://t.co/20ZwfcfdLU

[Imperative Care Stroke @ImpCare_Stroke]

NEWS: 📢 Today we announced the launch of our newest innovation in ischemic #stroke care: the #Zoom4S Catheter. Purposefully engineered for seamless #ZoomStrokeSystem compatibility, reduced catheter exchanges, and enhanced distal navigation and aspiration power – the new Zoom 4S brings the benefits of the ADAPT 2.0 technique to more occlusions with a single Zoom stack.

🔗 Read the press release for more: https://t.co/fWqn6Kxeky

#neurointervention
Rx only. ISI: https://t.co/20ZwfcfdLU

[Imperative Care Stroke @ImpCare_Stroke]

Innovation doesn’t stand still—and neither do we.

We’re headed to #ISC26 and can’t wait to see you there. Stay tuned to learn more about our advanced technologies and techniques, and swing by to try the #ZoomStrokeSystem for yourself!

#neurointervention @AHAScience
Rx only. ISI: https://t.co/20ZwfceFWm

[Imperative Care Stroke @ImpCare_Stroke]

Clinical data on ADAPT 2.0 using the #ZoomStrokeSystem to treat #stroke patients demonstrated a 98% rate of full clot ingestion and capture in one or both Zoom PODs. The analysis also showed that clot was observed in the Zoom 88 POD in 35% of cases, which may have otherwise been lost without continuous dual aspiration. These findings highlight the advantages of continuous dual aspiration (CDAT) in reducing risk of clot loss and enhancing overall control during stroke procedures.

🔗Learn more about how #CDAT can impact your practice: https://t.co/k1jdngXdpn

#neurointervention #mechanicalthrombectomy
Rx only. ISI: https://t.co/20ZwfceFWm

[Imperative Care Stroke @ImpCare_Stroke]

Clinical data on ADAPT 2.0 using the #ZoomStrokeSystem were presented in a late-breaking abstract at #SVIN25 demonstrating high rates of successful and excellent final reperfusion:

✅ 97% rate of final mTICI ≥ 2b
✅ 80% rate of final mTICI ≥ 2c

By getting closer to the clot with 0.088” intracranial access, achieving improved clot ingestion with asymmetric aspiration, and reducing the risk of lost clot with continuous dual aspiration (CDAT), ADAPT 2.0 offers physicians fast and effective clot removal during #stroke procedures.

🔗 Learn more about the ADAPT 2.0 approach with the Zoom Stroke System: https://t.co/GuACWgCmst

#neurointervention #mechanicalthrombectomy
Rx only. ISI: https://t.co/20ZwfceFWm

[Bijorn in USA @bradbourg]

@colem99926 @MatthewBrune_ @BengalTigerOn3 That is one hell of a word salad.

[Imperative Care Stroke @ImpCare_Stroke]

Every second matters when it comes stroke. Time=Brain!

Recent clinical data examining the ADAPT 2.0 approach using the #ZoomStrokeSystem to treat #stroke patients demonstrated a median procedure time of 17 minutes.

🔗 Learn more about the ADAPT 2.0 approach with the Zoom Stroke System: https://t.co/GuACWgCUi1

#ZoomStrokeSystem #stroke #neurointervention
Rx only. ISI: https://t.co/20ZwfcfdLU